Press releases
- Marzam's New Strategy Will Focus on Strengthening the Company's Position within Pharmaceutical Sector
- Agreement Signed for Share Redemption in Marzam
- Genomma Lab Internacional Announces Results for the First Quarter 2024
- Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call
- GENOMMA LAB INTERNACIONAL ANNOUNCES SEVENTH DIVIDEND PAYMENT
- Genomma Lab's ESG Rating Upgraded to A
- Genomma Lab Internacional Reports Fourth Quarter & Full Year 2023 Results
- EFFECTS OF ARGENTINA HYPERINFLATIONARY ACCOUNTING ON Q4 AND FULL YEAR 2023 RESULTS
More ▼
Key statistics
As of last trade Genomma Lab Internacional SAB de CV (GEKA:FRA) traded at 0.905, -3.72% below its 52-week high of 0.94, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.905 |
---|---|
High | 0.905 |
Low | 0.905 |
Bid | 0.945 |
Offer | 0.965 |
Previous close | 0.93 |
Average volume | 1.63k |
---|---|
Shares outstanding | 1.02bn |
Free float | 786.95m |
P/E (TTM) | 15.16 |
Market cap | 17.71bn MXN |
EPS (TTM) | 1.14 MXN |
Annual div (ADY) | 0.0343 EUR |
---|---|
Annual div yield (ADY) | 3.69% |
Div ex-date | Mar 21 2024 |
Div pay-date | Mar 25 2024 |
Data delayed at least 15 minutes, as of May 15 2024 07:28 BST.
More ▼